Free Access
Review
Issue
J Extra Corpor Technol
Volume 42, Number 2, June 2010
Page(s) 103 - 113
DOI https://doi.org/10.1051/ject/201042103
Published online 15 June 2010
  1. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–91. [CrossRef] [PubMed] [Google Scholar]
  2. Lewis HDJr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396–403. [CrossRef] [PubMed] [Google Scholar]
  3. Julian DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): A multicentre unblinded randomised clinical trial. BMJ. 1996;313:1429–31. [CrossRef] [PubMed] [Google Scholar]
  4. Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992;80:2006–11. [CrossRef] [PubMed] [Google Scholar]
  5. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation. 1997;95:63–8. [CrossRef] [PubMed] [Google Scholar]
  6. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–304. [CrossRef] [PubMed] [Google Scholar]
  7. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202–8. [CrossRef] [PubMed] [Google Scholar]
  8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502. [CrossRef] [PubMed] [Google Scholar]
  9. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation. 1994;89:588–95. [CrossRef] [PubMed] [Google Scholar]
  10. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925–34. [CrossRef] [Google Scholar]
  11. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–39. [CrossRef] [PubMed] [Google Scholar]
  12. Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J. 2000;140:67–73. [CrossRef] [PubMed] [Google Scholar]
  13. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17. [CrossRef] [PubMed] [Google Scholar]
  14. Ferguson AD, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability: Review of the published literature. Tex Heart Inst J. 2008;35:313–20. [Google Scholar]
  15. Coller BS. A new murine monoclonal antibody reports an activationdependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985;76:101–8. [CrossRef] [PubMed] [Google Scholar]
  16. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1–6. [CrossRef] [Google Scholar]
  17. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922–8. [CrossRef] [Google Scholar]
  18. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 2000;284:1549–58. [CrossRef] [PubMed] [Google Scholar]
  19. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895–903. [CrossRef] [PubMed] [Google Scholar]
  20. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA. 2005;293:1759–65. [CrossRef] [PubMed] [Google Scholar]
  21. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399–406. [CrossRef] [PubMed] [Google Scholar]
  22. Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: In vitro and in vivo/ex vivo studies. Stroke. 2003;34:764–9. [CrossRef] [PubMed] [Google Scholar]
  23. Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation. 1980;62:449–61. [CrossRef] [Google Scholar]
  24. The Persantine-Aspirin Reinfarction Study (PARIS) Research Group. The Persantine-aspirin reinfarction study. Circulation. 1980;62:V85–8. [PubMed] [Google Scholar]
  25. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol. 1986;7:251–69. [CrossRef] [Google Scholar]
  26. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet. 2006; 367:1665–73. [CrossRef] [PubMed] [Google Scholar]
  27. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21–6. [CrossRef] [PubMed] [Google Scholar]
  28. Douglas JSJr, Holmes DRJr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826–32. [CrossRef] [PubMed] [Google Scholar]
  29. Onoda K, Ohashi K, Hashimoto A, et al. Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery. Ann Thorac Cardiovasc Surg. 2008;14:230–7. [Google Scholar]
  30. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879–87. [CrossRef] [PubMed] [Google Scholar]
  31. Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol. 2006;546:142–7. [CrossRef] [Google Scholar]
  32. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51:3061–4. [CrossRef] [PubMed] [Google Scholar]
  33. Lasser G, Guchhait P, Ellsworth JL, et al. C1qTNF-related protein-1 (CTRP-1): A vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. Blood. 2006;107:423–30. [CrossRef] [PubMed] [Google Scholar]
  34. Bigalke B, Geisler T, Stellos K, et al. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J. 2008;156:193–200. [CrossRef] [Google Scholar]
  35. Meier TR, Myers DDJr, Wrobleski SK, et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost. 2008;99:343–51. [CrossRef] [PubMed] [Google Scholar]
  36. Ren YJ, Lu AG, Zhang GQ, Jia DH. Inhibitory effects of nimodipine on platelet aggregation and thrombosis. Acta Pharmacologica Sinica. 1998;19:158–60. [Google Scholar]
  37. Hsiao G, Ko FN, Jong TT, Teng CM. Antiplatelet action of 3’,4’-diisovalerylkhellactone diester purified from Peucedanum japonicum Thunb. Biol Pharm Bull. 1998;21:688–92. [CrossRef] [PubMed] [Google Scholar]
  38. Goldman S, Copeland J, Moritz T, et al. Internal mammary artery and saphenous vein graft patency. Effects of aspirin. Circulation. 1990; 82:IV237–42. [PubMed] [Google Scholar]
  39. Goldman S, Copeland J, Moritz T, et al. Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: Results of a VA Cooperative study. Circulation. 1994;89:1138–43. [CrossRef] [PubMed] [Google Scholar]
  40. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309–17. [CrossRef] [PubMed] [Google Scholar]
  41. Filion KB, Pilote L, Rahme E, Eisenberg MJ. Use of perioperative cardiac medical therapy among patients undergoing coronary artery bypass graft surgery. J Card Surg. 2008;23:209–15. [CrossRef] [PubMed] [Google Scholar]
  42. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28:616–26. [CrossRef] [Google Scholar]
  43. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy–II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994;308:159–68. [CrossRef] [PubMed] [Google Scholar]
  44. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106. [CrossRef] [PubMed] [Google Scholar]
  45. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy–III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235–46. [CrossRef] [PubMed] [Google Scholar]
  46. Ferraris VA, Ferraris SP, Joseph O, Wehner P, Mentzer RMJr. Aspirin and postoperative bleeding after coronary artery bypass grafting. Ann Surg. 2002;235:820–7. [CrossRef] [PubMed] [Google Scholar]
  47. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40:231–7. [CrossRef] [Google Scholar]
  48. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg. 2004;78:1536–41. [CrossRef] [Google Scholar]
  49. Kamran M, Ahmed A, Dar MI, Khan AB. Effect of aspirin on postoperative bleeding in coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2008;14:224–9. [Google Scholar]
  50. Sun JC, Whitlock R, Cheng J, et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: A systematic review of randomized and observational studies. Eur Heart J. 2008;29:1057–71. [CrossRef] [PubMed] [Google Scholar]
  51. Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg. 2000;70:1986–90. [CrossRef] [Google Scholar]
  52. Leong JY, Baker RA, Shah PJ, Cherian VK, Knight JL. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg. 2005;80:928–33. [CrossRef] [Google Scholar]
  53. Ouattara A, Bouzguenda H, Le Manach Y, et al. Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin. Eur Heart J. 2007;28:1025–32. [CrossRef] [PubMed] [Google Scholar]
  54. Bednar F, Osmancik P, Hlavicka J, Jedlickova V, Paluch Z, Vanek T. Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery. J Thromb Thrombolysis 2008;27:394–9. [Google Scholar]
  55. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2004;128:425–31. [CrossRef] [Google Scholar]
  56. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: A double-blind, placebocontrolled, randomized clinical trial. Circulation. 2005;112:I276–80. [CrossRef] [PubMed] [Google Scholar]
  57. Sirs JA, Glenville B, Stanbridge RL, et al. The influence of vascular pressure and different primes on the fluid balance of, and oxygen supply to, the patient during CABG. Perfusion. 1995;10:33–44. [CrossRef] [PubMed] [Google Scholar]
  58. Li S, Price R, Phiroz D, Swan K, Crane TA. Systemic inflammatory response during cardiopulmonary bypass and strategies. J Extra Corpor Technol. 2005;37:180–8. [Google Scholar]
  59. Farneti PA, Sbrana S, Spiller D, et al. Reduction of blood coagulation and monocyte-platelet interaction following the use of a minimal extracorporeal circulation system (Synergy) in coronary artery bypass grafting (CABG). Perfusion. 2008;23:49–56. [CrossRef] [PubMed] [Google Scholar]
  60. Clar A, Bowers MC, Larson DF. Derivation of sieving coefficients to determine the efficacy of the hemoconcentrator in removal of four inflammatory mediators produced during cardiopulmonary bypass. ASAIO J. 1997;43:163–70. [Google Scholar]
  61. Chen YF, Tsai WC, Lin CC, et al. Effect of leukocyte depletion on endothelial cell activation and transendothelial migration of leukocytes during cardiopulmonary bypass. Ann Thorac Surg. 2004; 78:634–42; discussion 642-33. [CrossRef] [Google Scholar]
  62. Sobieski MAII, Graham JD, Pappas PS, Tatooles AJ, Slaughter MS. Reducing the effects of the systemic inflammatory response to cardiopulmonary bypass: Can single dose steroids blunt systemic inflammatory response syndrome? ASAIO J. 2008;54:203–6. [CrossRef] [PubMed] [Google Scholar]
  63. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol. 2005;238:1–9. [CrossRef] [Google Scholar]
  64. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–4. [CrossRef] [PubMed] [Google Scholar]
  65. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047–54. [CrossRef] [PubMed] [Google Scholar]
  66. Lee Y, Lee WH, Lee SC, et al. CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology. 1999;92:11–6. [CrossRef] [PubMed] [Google Scholar]
  67. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107:1123–8. [CrossRef] [PubMed] [Google Scholar]
  68. Azar RR, Kassab R, Zoghbi A, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J. 2006;151:521.e1–521.e4. [CrossRef] [Google Scholar]
  69. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation. 2002;105:2849–54. [CrossRef] [PubMed] [Google Scholar]
  70. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001;103:2572–8. [CrossRef] [PubMed] [Google Scholar]
  71. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230–5. [CrossRef] [Google Scholar]
  72. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to lowdose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol. 2003;42:1115–9. [CrossRef] [Google Scholar]
  73. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. J Am Coll Cardiol. 2006;47:27–33. [CrossRef] [Google Scholar]
  74. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980–7. [CrossRef] [PubMed] [Google Scholar]
  75. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–17. [CrossRef] [PubMed] [Google Scholar]
  76. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation. 2003;107:32–7. [CrossRef] [PubMed] [Google Scholar]
  77. Borgdorff P, Tangelder GJ, Paulus WJ. Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. J Am Coll Cardiol. 2006;48:817–23. [CrossRef] [Google Scholar]
  78. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation. 2002;105:1620–2. [CrossRef] [PubMed] [Google Scholar]
  79. Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of antiplatelet drug resistance. Clin Genet. 2009;75:1–18. [CrossRef] [Google Scholar]
  80. Hobson AR, Agarwala RA, Swallow RA, Dawkins KD, Curzen NP. Thrombelastography: Current clinical applications and its potential role in interventional cardiology. Platelets. 2006;17:509–18. [CrossRef] [PubMed] [Google Scholar]
  81. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46:1705–9. [CrossRef] [Google Scholar]
  82. Bochsen L, Wiinberg B, Kjelgaard-Hansen M, Steinbruchel DA, Johansson PI. Evaluation of the TEG platelet mapping assay in blood donors. Thromb J. 2007;5:3. [CrossRef] [Google Scholar]
  83. Alstrom U, Tyden H, Oldgren J, Siegbahn A, Stahle E. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thromb Res. 2007;120:353–9. [CrossRef] [Google Scholar]
  84. Syrbe G, Redlich H, Weidlich B, et al. Individual dosing of ASA prophylaxis by controlling platelet aggregation. Clin Appl Thromb Hemost. 2001;7:209–13. [CrossRef] [PubMed] [Google Scholar]
  85. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331–6. [CrossRef] [PubMed] [Google Scholar]
  86. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86. [CrossRef] [PubMed] [Google Scholar]
  87. Serebruany VL, Malinin AI, Sane DC, et al. Magnitude and time course of platelet inhibition with Aggrenox and aspirin in patients after ischemic stroke: The AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol. 2004;499:315–24. [CrossRef] [Google Scholar]
  88. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: Position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005;3:1309–11. [CrossRef] [Google Scholar]
  89. Bedard PW, Clerin V, Sushkova N, et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther. 2008;324:497–506. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.